Stomach Tumors

Benign Tumors

Fundic Gland Polyps

Benign. Most common stomach polyp.

Hyperplastic expansion of deep oxyntic mucosa with cystically dilated oxyntic glands and foveolar hypoplasia. Parietal cell hyperplasia

Usually asymptomatic and incidental. Associated with PPI use
Can have CTNNB1 (β-catenin) mutations
If numerous (esp. >20) in a young patient, consider a polyposis syndrome, such as FAP.

Hyperplastic Polyps

Benign. Second most common gastric polyp

Elongated, tortuous, hyperplastic foveolar epithelium
Cystically dilated glands
Inflammatory changes and edema
Often eroded at surface.
Small, haphazardly distributed smooth muscle

Hyperproliferative response to tissue injury.
Usually arise in setting of long-standing gastritis
Precursor lesion = polypoid foveolar hyperplasia

May be hard to differentiate from hamartomatous polyps (e.g., Cronkhite-Canada syndrome)

Pyloric Gland adenoma

Polypoid proliferation of pyloric-type gastric glands (cuboidal to columnar cells with foamy, ground-glass cytoplasm) and no well-formed apical mucin cap. Often dilated glands. Basal round nuclei.

Usually older individuals with atrophic/metaplastic autoimmune gastritis and/or H. pylori

Sometimes syndromic (e.g., FAP, GAPPs, etc...)

Activating GNAS and/or KRAS mutations and inactivating APC mutations.

Can develop high-grade dysplasia → carcinoma
Stain with MUC6
Dysplasia

Neoplastic change of gastric epithelium without stromal invasion.

*Can be gastric/foveolar or intestinal-type (or mixed):*

**Intestinal-type dysplasia:** looks like a colonic adenoma with tall columnar cells with hyperchromatic nuclei.

**Gastric/Foveolar-type dysplasia** has tubulovillous or serrated fronds lined by cuboidal to columnar cells resembling gastric foveolar cells. Nuclei are round to oval. There is apical neutral mucin.

Regardless of type, graded as high vs low:

**Low-grade dysplasia:** preserved polarization (basal nuclei), relatively preserved architecture.

- **Intestinal:** nuclei hyperchromatic, elongate (“cigar-shaped”)
- **Foveolar:** nuclei round to oval

**High-grade dysplasia:** Prominent cytologic atypia with enlarged nuclei, high N:C ratios, sometimes prominent nucleoli. Loss of polarity. Complex architecture.

**Indefinite for dysplasia:** Not a biologic entity. Used when there are questions as to if a lesion is neoplastic or reactive. Often very inflamed.

**Intramucosal carcinoma**

→ Invasion into lamina propria
Characterized by gland crowding, excessive branching, and budding. Can see: Single cell infiltration, trabecular growth, intraglandular necrotic debris, and irregular gland fusion.

**Intestinal-type Adenoma**

*Localized, polypoid lesion* (whereas dysplasia can be flat and multifocal/non-localized) with dysplastic intestinalized epithelium.

Third-most common type of gastric polyp.

Any cause of gastric intestinalization is a risk factor (e.g., H. pylori, autoimmune gastritis, etc...)

Look similar to colorectal adenomas and have similar genetics.

**Rarer Polyps**

**Foveolar-type adenoma:** Similar to foveolar dysplasia (discussed above), but localized, polypoid lesion. Usually syndrome-associated (FAP or GAPPs), with no background of inflammation (unlike intestinal-type adenomas).

**Oxyntic gland adenoma:** Neoplasm composed of columnar cells with chief cell differentiation (pale basophilic cytoplasm) with mild nuclear atypia, mimicking oxyntic glands. High rate of progression to invasive adenocarcinoma.
Malignant Tumors

Adenocarcinoma

Malignant epithelial neoplasm with invasion of lamina propria (or beyond) by neoplastic glandular cells.

Risk factors:

H. pylori—very strong risk factor. Chronic infection $\rightarrow$ chronic inflammation $\rightarrow$ intestinal metaplasia $\rightarrow$ dysplasia $\rightarrow$ carcinoma.

Also—smoking, EBV-infection, and dietary factors

Morphological subtypes:

Tubular—most common subtype. Branching tubules of variable diameter. Solid growth with barely recognized tubules is included in this group.

Poorly cohesive (including signet ring)—Second most common. Neoplastic cells are isolated or arranged in small aggregates without well-formed glands.

Signet-ring cell type is composed predominantly or exclusively of signet ring cells, which are characterized by a central, optically clear, globoid droplet of cytoplasmic mucin with an eccentric nucleus.

Mucinous—malignant epithelium in extracellular mucin pools. Must be $>50\%$ of tumor. Tumor cells may be in glands or single cells.

Papillary—Relatively rare. Exophytic growth with elongated finger-like processes lined by cuboidal to columnar cells supported by fibrovascular cores. Well-differentiated with pushing invasion, but nevertheless has a worse prognosis.

Gastric (adeno)carcinoma with lymphoid stroma—(aka “lymphoepithelial-like carcinoma” or “medullary carcinoma”) Syncytial growth of irregular sheets and tubules of polygonal tumor cells with rich lymphocytic infiltrate. Often EBV-associated. A separate subset are MMR-deficient (so get EBV and MMR IHC on any case you are considering for this).

Hepatoid carcinoma—resemble liver (large polygonal eosinophilic cells). May stain with Hepar-1 and/or AFP. Usually Arginase-1 negative.

Micropapillary adenocarcinoma—small clusters of tumor cells without fibrovascular cores protruding into clear spaces. Worse prognosis (like micropapillary carcinomas in other organs).

Fundic-gland type—develop from oxyntic gland adenomas. Very rare!

Mixed—contain two or more subtypes. Often worse prognosis.
Molecular subtypes:

**Chromosomally unstable:** Predominantly intestinal type morphology with extensive DNA copy number variations. Frequent TP53 mutations. Most common subtype.

**Genomically stable:** Predominantly diffuse (signet-ring) morphology. Fewer genetic alterations. Frequent CDH1 and RHOA alterations/mutations.

**Microsatellite instability (MSI):** mutations or promoter methylation of mismatch repair enzymes (often MLH1). Better prognosis.

**EBV-positive:** usually histologically gastric carcinoma with lymphoid stroma. PIK3CA and ARID1A mutations. Often PD-L1 amplified. Better prognosis.

Staging:
Tumors with an epicenter within 2 cm of the GE junction should be staged as *esophageal* cancers. All tumors in the stomach that do not cross the GE junction (or have an epicenter in the stomach >2 cm from the GE junction) should be staged as gastric.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis</td>
<td>Carcinoma in situ = High-grade dysplasia</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor invades lamina propria or muscularis mucosae</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor invades submucosae</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor invades muscularis propria</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor invades subserosa</td>
</tr>
<tr>
<td>T4a</td>
<td>Tumor perforates serosa</td>
</tr>
<tr>
<td>T4b</td>
<td>Tumor invades adjacent structures</td>
</tr>
</tbody>
</table>

Predictive biomarkers:
Anti-**HER2 (ERBB2)** therapy is used in patients with unresectable or metastatic tumors. (see esophageal guide for grading scheme)

**EBV and MSI:** tumors that are EBV-positive or MSI-high are better prognosis.
Well-Differentiated Neuroendocrine Tumors

Proliferation of cells with round nuclei, “salt and pepper” (speckled) chromatin and abundant eosinophilic cytoplasm, arranged in nests, acini, trabeculae, and ribbons.

Express neuroendocrine (NE) markers: Synaptophysin, Chromogranin, INSM1

3 main clinical settings/types (see chart below):

**Type 1:** Associated with autoimmune gastritis → destruction of parietal cells → decreased stomach acid → compensatory hyperplasia of antral G-cells (to try to signal to make more acid) → secrete gastrin → ECL cell hyperplasia and NET formation

**Type 2:** Zollinger-Ellison syndrome with a duodenal or pancreatic gastrin-secreting NET, which stimulates ECL cell hyperplasia and stomach NET formation

**Type 3:** Sporadic, often higher stage and more aggressive.

**Size Requirements:** (this can vary a little by source, but generally...)

**NE cell hyperplasia:** collections of >5 NE cells. Can be linear (chain) or micronodular (clusters), <0.15mm

**NE cell dysplasia:** nodules > 0.15 mm, fused nodules, or infiltrative nodules (pTis)

**Micro-NET:** cellular proliferation filling lamina propria. Nodule >0.15mm, but < 0.5mm (pTis)

**NET:** >0.5mm or invasion into submucosa

**Grading:** Ki67 Proliferation index based on evaluation of ≥ 500 cells in a “hot spot.” Mitotic count based on evaluating 50 Hpf’s, but reported per 10 Hpf’s.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Ki67 Proliferation Index</th>
<th>Mitotic index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>&lt;3%</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Grade 2</td>
<td>3-20%</td>
<td>2-20</td>
</tr>
<tr>
<td>Grade 3</td>
<td>&gt;20%</td>
<td>&gt;20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type 1</th>
<th>Type 2</th>
<th>Type 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cause</td>
<td>Autoimmune gastritis</td>
<td>Zollinger-Ellison syndrome, often MEN1</td>
</tr>
<tr>
<td>Focality</td>
<td>Multifocal</td>
<td>Multifocal</td>
</tr>
<tr>
<td>Cell of origin</td>
<td>ECL (body/fundus)</td>
<td>ECL (body/fundus)</td>
</tr>
<tr>
<td>% of Gastric NET’s</td>
<td>~85%</td>
<td>~5%</td>
</tr>
<tr>
<td>Hypergastrinemia</td>
<td>Yes (secondary)</td>
<td>Yes (primary)</td>
</tr>
<tr>
<td>ECL-cell proliferation</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Acid secretion</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Background mucosa</td>
<td>Atrophic gastritis</td>
<td>Parietal cell hyperplasia</td>
</tr>
<tr>
<td>Stage at Dx:</td>
<td>Low (Tx = EMR)</td>
<td>Low (usually)</td>
</tr>
<tr>
<td>5-year survival</td>
<td>~100%</td>
<td>~75%</td>
</tr>
</tbody>
</table>
Lymphoma
The GI tract is the most common site of extranodal lymphomas and the stomach is the most commonly involved site. The two most common are DLBCL and extranodal marginal zone lymphoma.

Diffuse Large B-Cell Lymphoma (DLBCL)—Diffuse infiltrate of atypical large lymphoid cells that show immunoreactivity to B cell markers (CD20, PAX5, CD19, CD79a) and are negative for EBV. Most cells resemble centroblasts. Tend to localize to one anatomical site and are less aggressive than their nodal counterpart. However, like nodal disease, must still do full work-up to classify as Germinal center (GCB) or Activated B Cell (ABC) subtypes and look for MYC and BCL2 alterations.


Squamous cell carcinoma—carcinoma with exclusively squamous differentiation, with keratinocyte-cells with intercellular bridges and/or keratinization. Very rare.

Adenosquamous carcinoma—carcinoma with both glandular and squamous differentiation (with each at least 25%).

Undifferentiated carcinoma—carcinoma composed of anaplastic cells without histologic or immunophenotypic evidence of differentiation. Diffuse malignant cells. Often patchy keratin. Dx of exclusion—must rule out lymphoma, melanoma, EBV-associated gastric carcinoma, etc...

Gastroblastoma—Often young men. Biphasic tumor of gastric muscularis propria with spindled cells and nests of epithelial cells. MALAT1-GLI1 gene fusion